![]() |
市場調查報告書
商品編碼
2000415
建築生醫材料市場預測至2034年-按材料類型、功能、技術、通路、應用、最終用戶和地區分類的全球分析Living Materials for Construction Market Forecasts to 2034 - Global Analysis By Material Type, Functionality, Technology, Distribution Channel, Application, End User, and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球建築用生物材料市場規模將達到 11 億美元,並在預測期內以 14.2% 的複合年成長率成長,到 2034 年將達到 32 億美元。
用於建築的生物材料是利用合成生物學、生物技術和先進材料科學設計的生物活性建築材料,其功能超越了被動的結構作用。這些材料包括利用細菌礦化作用的自修復生物混凝土、菌絲體基複合板、藻類建築覆材、固碳生物複合材料以及能夠自主維持、修復或隨時間推移調整自身性能的生物工程結構構件。其主要功能包括自修復能力、碳捕獲與儲存、溫度調節、濕度管理以及在住宅、商業、工業和基礎設施建設應用中提高結構耐久性。
碳中和將加速生物材料的應用。
各國紛紛做出淨零排放承諾,國際氣候變遷協議也要求建設產業履行脫碳義務,這促使人們對能夠固碳並主動減少建築物排放的「活性材料」產生了濃厚的興趣。光是混凝土生產就佔全球二氧化碳排放的約8%,因此,監管和市場對生物相容性替代品的壓力日益增加。自修復生物混凝土和固碳生物複合材料具有引人注目的永續性特徵,能夠滿足綠建築認證和投資者對環境、社會和治理(ESG)的要求。政府採購計畫優先考慮低碳建築材料,以及企業不斷增加的淨零排放承諾,正在加速實驗室創新向商業建築實用化的轉化。
生產規模化和品質穩定性是面臨的挑戰。
生物材料在生產規模化方面面臨巨大挑戰,與傳統建築材料相比,商業性競爭力受到嚴重限制。生物製造程序,例如菌絲複合複合材料、細菌混凝土和藻類板的生產,需要嚴格控制的環境條件、較長的生產週期和穩定的質量,這顯著增加了製造成本。目前的產量不足以滿足主流建築採購需求,為大型計劃開發商帶來供應鏈風險。對於市場參與企業而言,實現穩定的機械性能並符合建築規範和保險公司要求的標準化認證標準,仍然是一項技術難度高且資源密集的任務。
政府資金支持綠建築加速商業化
美國、歐盟、英國和新加坡的大規模政府資助項目正透過研發津貼、採購優先政策和創新基礎設施示範計劃,加速生物建築材料的商業化進程。例如,美國能源部高級研究計畫署(ARPA-E)的「生物啟發式建築材料舉措」和歐盟的「地平線綠色建築創新叢集」等項目,為處於商業化規模化生產前期的生物材料公司提供了必要的資金和市場准入。具有里程碑意義的公共部門計劃將生物建築材料應用於實踐,提高了公眾認知度,檢驗了概念驗證(PoC),增強了採購信譽,從而促進了私營部門對生物建築材料的採用,並吸引了後續的私人投資。
《建築標準法》下的核准流程會延緩市場進入。
大多數地區的建築規範和建築材料標準都基於擁有數十年性能數據的傳統無機材料,這為新型生物來源建築材料的認證設置了重大障礙。結構安全機構要求提供大量的測試數據、長期耐久性數據和標準化的性能基準,而生物材料公司目前仍在累積這些數據。在主要市場獲得建築規範認證可能需要數年時間,這會延緩商業性盈利,並給Start-Ups帶來融資負擔。此外,結構設計公司和總承包商往往較為保守,在客戶計劃中採用未經驗證的生物來源建築材料之前,他們會要求這些材料有足夠的成功案例。
新冠疫情加劇了建設產業對依賴傳統材料所帶來的供應鏈脆弱性的認知,同時也提升了相關人員對永續和循環建築實踐的關注。疫情對傳統建築材料供應鏈造成的衝擊,促使人們接受本地生產的、供應鏈更短、更具韌性的生物基替代品,例如菌絲複合複合材料和生物混凝土系統。歐洲和北美政府的經濟復甦計劃,以及強力的綠色建築要求,加速了對創新生醫材料研發和先導計畫的投資。疫情後的環境、社會和治理(ESG)投資指令進一步提升了機構投資者對生物材料作為淨零排放建築策略組成部分的興趣。
在預測期內,細菌礦化材料細分市場預計將佔據最大的市場佔有率。
在預測期內,細菌礦化材料領域預計將佔據最大的市場佔有率。這主要歸功於其成熟且商業性程度高的自修復混凝土應用,這些應用已獲得多個司法管轄區的監管核准,並吸引了建設產業的巨額投資。細菌礦化技術具有可衡量的結構修復性能,並有不斷成長的臨床證據支持,使其成為生物材料領域商業性化程度最高的技術,並有望在預測期內成為主要的收入來源。
在預測期內,自癒功能細分市場預計將呈現最高的複合年成長率。
在預測期內,自修復功能細分市場預計將呈現最高的成長率,這主要得益於監管機構日益成長的壓力,旨在降低公共基礎設施的生命週期維護成本,以及在人工維護困難或成本過高的應用領域,對自主結構修復的需求不斷成長。隨著氣候變遷加劇建築物和基礎設施的結構荷載,自修復材料的功能正吸引前所未有的投資和規格關注,預計該功能細分市場將在整個預測期內保持最高的成長率。
在預測期內,歐洲地區預計將佔據最大的市場佔有率。這得歸功於歐盟綠色交易、嚴格的建築材料碳排放法規,以及致力於永續材料創新、前瞻性的建設產業。荷蘭、德國、英國和斯堪地那維亞國家擁有最集中的生物材料研究機構、Start-Ups和試點建設計劃。政府對生物基建築創新和循環經濟建築標準的大力公共資金支持,為永續市場發展創造了有利環境。
在預測期內,北美預計將呈現最高的複合年成長率,這主要得益於美國能源部高級研究計劃署 (ARPA-E) 和美國能源部 (DOE) 的大量研究經費、大型房地產開發商不斷擴大的永續性舉措,以及生醫材料領域蓬勃發展的深科技Start-Ups生態系統。美國在菌絲複合材料和生物混凝土技術的研究成果和早期商業性應用方面均處於主導地位。 LEED 和 WELL 建築認證的日益普及正在創造對創新生物基材料的需求。像 CarbonCure Technologies 這樣的公司正在展示商業性可行的發展路徑,這鼓勵了現有建材公司進行更多投資並進入市場。
According to Stratistics MRC, the Global Living Materials for Construction Market is accounted for $1.1 billion in 2026 and is expected to reach $3.2 billion by 2034 growing at a CAGR of 14.2% during the forecast period. Living materials for construction refer to biologically active building materials engineered through synthetic biology, biotechnology, and advanced material science to perform active functions beyond passive structural roles. These materials include self-healing bio-concrete utilizing bacterial mineralization, mycelium-based composite panels, algae-integrated building skins, carbon-sequestering biocomposites, and bio-engineered structural components that autonomously maintain, repair, or adapt their properties over time. Core functionalities include self-healing capability, carbon capture and storage, thermal regulation, moisture management, and enhanced structural durability across residential, commercial, industrial, and infrastructure construction applications.
Carbon neutrality mandates accelerating bio-material adoption
The construction industry's obligation to decarbonize under national net-zero commitments and international climate agreements is driving serious interest in living materials capable of sequestering carbon and actively reducing embodied emissions in buildings. Concrete production alone accounts for approximately 8% of global CO2 emissions, creating regulatory and market pressure for biocompatible alternatives. Self-healing bio-concrete and carbon-sequestering biocomposites offer compelling sustainability profiles that align with green building certification requirements and investor ESG mandates. Government procurement programs favoring low-carbon building materials and growing corporate net-zero commitments are accelerating the transition from laboratory innovation toward commercial construction deployment.
Scalable manufacturing and quality consistency challenging
Living materials face substantial production scalability challenges that significantly limit their commercial competitiveness relative to conventional construction materials. Biological manufacturing processes for mycelium composites, bacterial concrete, and algae panels require precisely controlled environmental conditions, extended production timelines, and quality consistency challenges that increase manufacturing costs dramatically. Current production volumes are insufficient to meet mainstream construction procurement volumes, creating supply chain risk for large project developers. Achieving the mechanical performance consistency and standardized certification compliance required by building codes and insurance providers remains technically demanding and resource-intensive for early-stage market participants.
Government green construction funding accelerating commercialization
Significant government funding programs in the United States, European Union, United Kingdom, and Singapore are accelerating the commercialization of living construction materials through R&D grants, procurement preference policies, and innovative infrastructure demonstration projects. Programs such as the US ARPA-E bio-inspired building materials initiative and EU Horizon green construction innovation clusters are providing capital and market access critical for bio-material companies at the pre-commercial scale-up stage. Public sector landmark projects incorporating living materials provide visibility, proof-of-concept validation, and procurement credibility that facilitates private sector adoption and attracts subsequent private investment rounds.
Building code approval timelines delaying commercial entry
Building codes and construction material standards in most jurisdictions are designed around traditional inorganic materials with decades of performance data, creating significant certification hurdles for novel biological construction materials. Structural safety authorities require extensive testing evidence, long-term durability data, and standardized performance benchmarks that living materials companies are still accumulating. The multi-year timeline required to achieve building code recognition in key markets delays commercial revenue generation and strains startup financing. Additionally, structural engineering firms and general contractors are conservative adopters who require substantial track records before specifying unproven biological materials in client projects.
COVID-19 reinforced the construction industry's awareness of supply chain vulnerability associated with conventional material dependencies, simultaneously elevating stakeholder focus on sustainable and circular building practices. The pandemic's disruption to traditional material supply chains created receptivity toward locally produced bio-based alternatives with shorter, more resilient supply chains including mycelium composites and bio-concrete systems. Government economic recovery programs in Europe and North America with strong green construction conditions accelerated investment in innovative bio-material R&D and pilot projects. Post-pandemic ESG investment mandates have further elevated institutional interest in living materials as components of net-zero building strategies.
The bacterial mineralization materials segment is expected to be the largest during the forecast period
The bacterial mineralization materials segment is expected to account for the largest market share during the forecast period, owing to their proven, commercially advancing self-healing concrete applications that are achieving regulatory recognition in multiple jurisdictions and attracting substantial construction industry investment. Bacterial mineralization delivers measurable structural repair performance supported by an expanding clinical evidence base, positioning it as the most commercially mature technology within the living materials segment and the leading revenue contributor during the forecast period.
The self-healing capability segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the self-healing capability segment is predicted to witness the highest growth rate, reinforced by intensifying regulatory pressure to reduce lifecycle maintenance costs in public infrastructure and growing demand for autonomous structural repair in applications where manual maintenance is difficult or prohibitively expensive. As climate change accelerates structural stress on buildings and infrastructure, self-healing material functionality is attracting unprecedented investment and specification interest, positioning this functionality segment for the highest growth rate throughout the forecast period.
During the forecast period, the Europe region is expected to hold the largest market share, supported by the EU Green Deal, stringent embodied carbon regulations, and a progressive architectural and construction industry with appetite for sustainable material innovation. The Netherlands, Germany, the United Kingdom, and Scandinavian countries have the highest concentration of living materials research institutions, startup companies, and pilot construction projects. Strong public funding support for bio-based construction innovation and circular economy building standards create a favorable environment for sustained market development.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by substantial ARPA-E and DOE research funding, growing corporate sustainability commitments from major real estate developers, and an active deep-tech startup ecosystem in biomaterials. The United States leads in both research output and early commercial deployment of mycelium composites and bio-concrete technologies. Growing LEED and WELL building certification adoption is creating demand for innovative bio-based materials. Companies such as CarbonCure Technologies have demonstrated commercially viable pathways, encouraging further investment and market entry by established construction materials companies.
Key players in the market
Some of the key players in Living Materials for Construction Market include BASF SE, Holcim Ltd., Heidelberg Materials AG, Saint-Gobain S.A., CEMEX, S.A.B. de C.V., LafargeHolcim Ltd., Skanska AB, CRH plc, Sika AG, Arkema S.A., Dow Inc., Kingspan Group plc, Boral Limited, Ferrovial S.A., Vinci S.A., China State Construction Engineering Corporation, Aditya Birla Group, and CarbonCure Technologies Inc.
In March 2026, BASF launched its BioConstruct AI suite, integrating living polymers with adaptive building materials. The innovation enhances self-healing capacity, reduces maintenance costs, and supports sustainable urban infrastructure through recyclable, high-performance composites.
In February 2026, Holcim unveiled its EcoGrowth Concrete platform, embedding AI-driven microbial modeling into construction workflows. Tailored for green buildings, it improves durability, reduces carbon footprint, and enables scalable deployment in climate-resilient projects.
In January 2026, Heidelberg introduced its SmartBioCement system, combining AI algorithms with bio-mineralization processes. Designed for residential and commercial applications, it accelerates curing, enhances strength, and supports circular economy initiatives in construction.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.